Harrow, Inc. (HROW)
NASDAQ: HROW · Real-Time Price · USD
32.81
-0.61 (-1.83%)
Aug 5, 2025, 12:02 PM - Market open
Harrow Revenue
Harrow had revenue of $47.83M in the quarter ending March 31, 2025, with 38.29% growth. This brings the company's revenue in the last twelve months to $212.86M, up 53.49% year-over-year. In the year 2024, Harrow had annual revenue of $199.61M with 53.32% growth.
Revenue (ttm)
$212.86M
Revenue Growth
+53.49%
P/S Ratio
5.61
Revenue / Employee
$557,220
Employees
382
Market Cap
1.20B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 199.61M | 69.42M | 53.32% |
Dec 31, 2023 | 130.19M | 41.60M | 46.95% |
Dec 31, 2022 | 88.60M | 16.12M | 22.24% |
Dec 31, 2021 | 72.48M | 23.61M | 48.30% |
Dec 31, 2020 | 48.87M | -2.29M | -4.48% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
HROW News
- 7 days ago - Harrow To Report Second Quarter 2025 Financial Results After Market Close on August 11, 2025 - GlobeNewsWire
- 19 days ago - Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States - Business Wire
- 19 days ago - Samsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United States - Business Wire
- 21 days ago - HROW Investors Have Opportunity to Join Harrow, Inc. Fraud Investigation with the Schall Law Firm - PRNewsWire
- 24 days ago - Harrow's Internal $100 Price Target Is Ambitious, But New Bloomberg Data Backs It Up - Seeking Alpha
- 26 days ago - Harrow: Immense Upside Potential - Seeking Alpha
- 6 weeks ago - Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications - Business Wire
- 7 weeks ago - I Am Swimming In Dividends With +7% Yields - Seeking Alpha